LETTER TO THE EDITOR

Open Access



The negative relationship between patients with NSCLC harbored STK11/KEAP1 copy number variation and immune microenvironment infiltration

Chenyue Zhang^{1,2*}

To the editor,

Studies have found STK11 mutation resistant to immune checkpoint inhibitors (ICIs) and worse survival in KEAP1 mutant patients compared with wildtype in response to ICIs [1, 2]. It has demonstrated that less immune cell infiltration could be found in patients with non-small cell lung cancer (NSCLC) harbored STK11/KEAP1 mutation, which maybe lead to the resistance or worse survival to immune checkpoint inhibitors (ICIs) [3, 4]. However, there have been no relevant studies investigating the association between STK11/KEAP1 copy number variation and immune microenvironment in patients with NSCLC. In this regard, we aim to interrogate the immune microenvironment in patients with NSCLC harboring STK11/KEAP1 copy number variation.

In the present study, we conducted an analysis by evaluating the immuno-contexture in patients with lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) harboring STK11/KEAP1 copy number variation using TIMER databases [5, 6]. We compared the tumor infiltration immune cells with different copy number variation including deep deletion, arm-level deletion, diploid/normal, arm-level gain, high amplification for KEAP1 and STK11 in LUAD and LUSC. The immune cells tested were primarily responsible for efficacious

antitumor immunity, characterized by CD8+T cell, CD4+T cell and myeloid dendritic cell.

The results showed that for LUAD, arm level gain of STK11 was associated with debilitated immersion of CD8+T cell (P=0.0062). And arm level deletion of STK11 was correlated with CD4+T cell infiltration (P=0.0016). Both arm level deletion (P=8.4e-06) and arm level gain (P=0.0085) of STK11 was related with myeloid dendritic cells (Fig. 1A). For LUSC, the association could be found between STK11 arm level gain and CD8+T cell (P=0.034), between STK11 arm level deletion (P=0.023) and myeloid dendritic cells, between STK11 arm level gain (P=0.00033) and myeloid dendritic cells (Fig. 1B).

As we further explored, the association of KEAP1 deep deletion (P=0.027), arm level deletion (P=0.0042) with CD4+T cell infiltration was found in LUAD. And arm level deletion (P=5.4e-06), arm level gain (P=0.063) of KEAP1 were found to be linked with myeloid dendritic cells in LUAD (Fig. 1C). For LUSC, arm level gain of KEAP1 was associated with relatively less myeloid dendritic cell infiltration, as demonstrated in Fig. 1D.

In conclusion, for the first time, we have demonstrated the existence of dampened immune microenvironment in patients with NSCLC harboring STK11/KEAP1 copy number variation. However, it has to be noted that not all forms of copy number variation are linked with less immune cell immersion. Our study provides new insights into the immunological landscape of NSCLC harboring STK11/KEAP1 copy number variation, with relevance for

Full list of author information is available at the end of the article



© The Author(s) 2021. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

^{*}Correspondence: zhangchenyue_yazi@126.com

¹ Department of Integrated Therapy, Fudan University Shanghai Cancer Center, Shanghai 200032, China

Zhang *J Transl Med* (2021) 19:259 Page 2 of 3




Fig. 1 The association between patients with NSCLC harboring STK11/KEAP1 copy number variation and immune microenvironment infiltration. **A** The association between STK11 copy number alterations (deep deletion, arm-level deletion, diploid/normal, arm-level gain) and the infiltration of immune cells (CD8+T cell, CD4+T cells, myeloid dendritic cell) was analyzed in lung adenocarcinoma. **B** The association between STK11 copy number alterations (deep deletion, arm-level deletion, diploid/normal, arm-level gain) and the infiltration of immune cells (CD8+T cell, CD4+T cells, myeloid dendritic cell) was analyzed in lung squamous cell carcinoma. **C** The association between KEAP1 copy number alterations (deep deletion, arm-level deletion, diploid/normal, arm-level gain) and the infiltration of immune cells (CD8+T cell, CD4+T cells, myeloid dendritic cell) was analyzed in lung adenocarcinoma. **D** The association between KEAP1 copy number alterations (arm-level deletion, diploid/normal, arm-level gain, high amplification) and the infiltration of immune cells (CD8+T cell, CD4+T cells, myeloid dendritic cell) was analyzed in lung squamous cell carcinoma

Zhang J Transl Med (2021) 19:259 Page 3 of 3

therapeutic intervention. For patients with NSCLC harboring some forms of STK11/KEAP1 copy number variation, little immune cell infiltration is involved. Therefore, more complex treatment strategies may be needed to rekindle immune responses.

Acknowledgements

None

Authors' contributions

 ${\sf CZ}$ designed the study, performed data analysis, wrote the manuscript. The author read and approved the final manuscript.

Funding

This study was supported by National Natural Science Foundation of China (No. 82003996).

Availability of data and materials

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate

Since the study is based on public data, the informed consent and ethical proof are not required.

Consent for publication

Not applicable.

Competing interests

The author declared no competing interests.

Author details

¹Department of Integrated Therapy, Fudan University Shanghai Cancer Center, Shanghai 200032, China. ²Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.

Received: 29 May 2021 Accepted: 3 June 2021 Published online: 14 June 2021

References

- Skoulidis F, Goldberg ME, Greenawalt DM, Hellmann MD, Awad MM, Gainor JF, et al. STK11/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma. Cancer Discov. 2018;8(7):822–35.
- Chen X, Su C, Ren S, Zhou C, Jiang T. Pan-cancer analysis of KEAP1 mutations as biomarkers for immunotherapy outcomes. Ann Transl Med. 2020;8(4):141.
- Marinelli D, Mazzotta M, Scalera S, Terrenato I, Sperati F, D'Ambrosio L, et al. KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden. Ann Oncol. 2020;31(12):1746–54.
- Wang H, Guo J, Shang X, Wang Z. Less immune cell infiltration and worse prognosis after immunotherapy for patients with lung adenocarcinoma who harbored STK11 mutation. Int Immunopharmacol. 2020;84:106574.
- Li T, Fan J, Wang B, Traugh N, Chen Q, Liu JS, et al. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 2017;77(21):e108–10.
- Li B, Severson E, Pignon JC, Zhao H, Li T, Novak J, et al. Comprehensive analyses of tumor immunity: implications for cancer immunotherapy. Genome Biol. 2016;17(1):174.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- $\bullet\,$ thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

